HELIOS Klinikum Erfurt GmbH
- Address
- lock Available on a paid plan
Cardiovascular Diseases
At HELIOS Klinikum Erfurt the cardiovascular program focuses on improving outcomes after heart attacks and managing chronic heart failure, while also addressing resistant and uncontrolled hypertension.
- Acute coronary syndrome (STEMI/NSTEMI)
- Heart failure with reduced ejection fraction
- Acute heart failure
- Left‑sided heart failure
- Resistant hypertension
- Uncontrolled hypertension
- Myocardial infarction
The department has contributed to 52 clinical trials with 27 investigators, advancing treatment options for patients with cardiovascular conditions.
Congenital, Hereditary, and Neonatal Diseases
Research in this area explores rare genetic and neonatal disorders, aiming to refine diagnostic strategies and early therapeutic interventions for vulnerable infants.
- Preterm infants with gestational age 23+0/7 – 27+6/7 weeks
- Low‑risk neuroblastoma
- Intermediate‑risk neuroblastoma
- Congenital renal anomalies
Studies at the site support the development of precision medicine approaches for children born with hereditary conditions.
Hemic and Lymphatic Diseases
The hematology portfolio targets blood‑borne cancers and related disorders, testing novel targeted and immunotherapeutic agents to enhance remission and survival.
- Acute lymphoblastic leukemia (ALL)
- Acute myeloid leukemia (AML)
- Chronic lymphocytic leukemia (CLL)
- Lymphoblastic lymphoma
- Relapsed acute lymphoblastic leukemia
- Relapsed/refractory follicular lymphoma
- High‑risk neuroblastoma
With 27 investigators, the department drives innovative trials that evaluate proteasome inhibition, bispecific antibodies, and CAR‑T strategies for hematologic malignancies.
Neoplasms
Oncology trials span skin, solid organ, and brain tumors, evaluating new combinations of immunotherapy, targeted agents, and radiation to increase survival and quality of life.
- Advanced melanoma
- Basal cell carcinoma
- Merkel cell carcinoma
- Renal cell carcinoma
- Non‑small cell lung cancer (NSCLC)
- Small cell lung cancer (SCLC)
- Glioblastoma
- Ewing sarcoma
- Medulloblastoma
- Vestibular schwannoma
The site’s 52 trials include investigations of checkpoint inhibitors, BRAF/MEK inhibitors, and novel antibody‑drug conjugates to address unmet needs across tumor types.
Nervous System Diseases
Neurology research addresses acute cerebrovascular events, brain tumors, and neuro‑degenerative disorders, seeking faster reperfusion methods and disease‑modifying therapies.
- Acute ischemic stroke
- Acute ischemic stroke with direct oral anticoagulant use
- Acoustic schwannoma
- Glioblastoma
- Medulloblastoma
- Secondary progressive multiple sclerosis
- Ewing sarcoma (central nervous system involvement)
Collaborative efforts at HELIOS Klinikum Erfurt aim to improve functional outcomes after stroke and to test innovative agents for malignant brain tumors.
Miscellaneous Research
Additional studies cover diverse conditions that do not fit into the other categories, ranging from inflammation‑driven cardiovascular risk to novel lipid‑lowering therapies.
- Resistant hypertension
- Uncontrolled hypertension
- Ziltivekimab for inflammation reduction
- Inclisiran for LDL‑C lowering
- Remibrutinib for secondary progressive multiple sclerosis
These trials reflect the site’s commitment to addressing a broad spectrum of health challenges through rigorous clinical investigation.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 of 7 therapeutic areas and 15 of 145 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 110 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 26 by active trials.
- 1GPOH gGmbH6active
lock +25 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1GPOH gGmbH6trials
lock +12 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in HELIOS Klinikum Erfurt GmbH
lock Showing 1 of 57 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2 Peri-operative Trial of Fianlimab and Cemiplimab Compared with Anti-PD1 Alone in Patients with Resectable Stage III and IV Melanoma | Regeneron Pharmaceuticals Inc. | Phase II | Not Recruiting | Oct 2024 | — |
IMP list
lock Showing 1 of 145 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Etoposide | 14 | Unknown | 2015-06-02 | 2025-12-19 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.